Admagin-P Liquid Injection

Generic Name– Pegaspargase (Peg L-Asparaginase)
Drug Class – Antineoplastic agent

Peg L-Asparaginase is a chemotherapy drug used to treat acute lymphoblastic leukemia (ALL), a cancer of the white blood cells.
It works by breaking down asparagine, an amino acid that leukemia cells need to survive, thereby inhibiting their growth.
Peg L-Asparaginase is administered by intravenous (IV) infusion or intramuscular (IM) injection in hospital settings.
It is often used in combination with other chemotherapy agents as part of multi-drug treatment regimens.
Common side effects include allergic reactions, nausea, vomiting, fatigue, liver enzyme elevation, and pancreatitis.

Dosage: Available in 3750 IU/5 mL strength

Category: Liquid Injection

Category: Liquid Injections

Indications & Usage

Dydrogesterone is indicated for:

Prevention of natural abortion in adult patients who have a history of habitual abortions (Threatened or Recurrent Miscarriage)
Treatment option for patients with dysmenorrhea (severe and frequent menstrual cramps and pain during the period)
Treatment of endometriosis, a condition with abdominal pain and menstrual irregularities as common symptoms

Clinical Efficacy

First clinical treatment choice due to its the good oral bioavailability and lesser risk of developing breast or endometrial cancer compared to other progestagens
Shown to have significant improvements in pelvic pain, dysmenorrhea and dyspareunia, and a high level of satisfaction in the post-laparoscopic in women with endometriosis
More effective than conservative treatment in maintaining pregnancy in women with threatened miscarriage
Effectively improves hormone levels and related cellular immune factors in recurrent spontaneous abortion (RSA) patients
Regularize menstrual-cycle in women with abnormal uterine bleeding – ovulatory dysfunction

Safety Information

Adverse Reactions

The most common adverse events that occurs after administration of dydrogesterone are vaginal hemorrhage, nausea, vomiting, migraines or headaches, abdominal pain, menstrual complaints, and breast pain or tenderness

Contraindications

It is contraindicated in patients with a known hypersensitivity to dydrogesterone or any other ingredient present in formulation
Undiagnosed vaginal bleeding
Treatment for luteal support as part of an Assisted Reproductive Technology (ART) treatment should be discontinued upon diagnosis of abortion/miscarriage
Contraindications for the use of estrogens when used in combination with dydrogesterone

Special Precautions

The etiology for the bleeding should be clarified before starting the dydrogesterone treatment
Use dydrogesterone cautiously in patients with acute liver disease or a history of liver disease, discontinuing in severe cases
Breakthrough bleeding and spotting in the initial months of dydrogesterone treatment may warrant investigation, including endometrial biopsy, if they persist or recur after treatment cessation
Close supervision is advised for patients with a history of or predisposition to porphyria, or abnormal liver function during pregnancy or previous hormone treatment, considering potential recurrence or aggravation during dydrogesterone treatment, with discontinuation as an option
Patients with a history of depression may require vigilant monitoring, and if severe depression reoccurs, dydrogesterone treatment should be discontinued
In cases of habitual or threatened abortion, confirm fetal viability and monitor ongoing pregnancy progress and embryo vitality during treatment with dydrogesterone
Dydrogesterone has increased metabolism with CYP enzyme inducers (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, efavirenz, nevirapine)
Perform regular physical exams (including breast and pelvic tests, mammograms, blood pressure monitoring and Pap smears) is advised before and during dydrogesterone treatment
Dydrogesterone may cause drowsiness or dizziness, especially after intake; use caution when driving or operating machinery